Jens Christian Jensenius

Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations. / Świerzko, Anna S; Michalski, Mateusz; Sokołowska, Anna; Nowicki, Mateusz; Szala-Poździej, Agnieszka; Eppa, Łukasz; Mitrus, Iwona; Szmigielska-Kapłon, Anna; Sobczyk-Kruszelnicka, Małgorzata; Michalak, Katarzyna; Gołos, Aleksandra; Wierzbowska, Agnieszka; Giebel, Sebastian; Jamroziak, Krzysztof; Kowalski, Marek L; Brzezińska, Olga; Thiel, Steffen; Matsushita, Misao; Jensenius, Jens C; Gajek, Gabriela; Cedzyński, Maciej.

In: Frontiers in Immunology, Vol. 10, 3097, 01.2020.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Świerzko, AS, Michalski, M, Sokołowska, A, Nowicki, M, Szala-Poździej, A, Eppa, Ł, Mitrus, I, Szmigielska-Kapłon, A, Sobczyk-Kruszelnicka, M, Michalak, K, Gołos, A, Wierzbowska, A, Giebel, S, Jamroziak, K, Kowalski, ML, Brzezińska, O, Thiel, S, Matsushita, M, Jensenius, JC, Gajek, G & Cedzyński, M 2020, 'Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations', Frontiers in Immunology, vol. 10, 3097. https://doi.org/10.3389/fimmu.2019.03097

APA

Świerzko, A. S., Michalski, M., Sokołowska, A., Nowicki, M., Szala-Poździej, A., Eppa, Ł., Mitrus, I., Szmigielska-Kapłon, A., Sobczyk-Kruszelnicka, M., Michalak, K., Gołos, A., Wierzbowska, A., Giebel, S., Jamroziak, K., Kowalski, M. L., Brzezińska, O., Thiel, S., Matsushita, M., Jensenius, J. C., ... Cedzyński, M. (2020). Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations. Frontiers in Immunology, 10, [3097]. https://doi.org/10.3389/fimmu.2019.03097

CBE

Świerzko AS, Michalski M, Sokołowska A, Nowicki M, Szala-Poździej A, Eppa Ł, Mitrus I, Szmigielska-Kapłon A, Sobczyk-Kruszelnicka M, Michalak K, Gołos A, Wierzbowska A, Giebel S, Jamroziak K, Kowalski ML, Brzezińska O, Thiel S, Matsushita M, Jensenius JC, Gajek G, Cedzyński M. 2020. Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations. Frontiers in Immunology. 10:Article 3097. https://doi.org/10.3389/fimmu.2019.03097

MLA

Vancouver

Świerzko AS, Michalski M, Sokołowska A, Nowicki M, Szala-Poździej A, Eppa Ł et al. Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations. Frontiers in Immunology. 2020 Jan;10. 3097. https://doi.org/10.3389/fimmu.2019.03097

Author

Świerzko, Anna S ; Michalski, Mateusz ; Sokołowska, Anna ; Nowicki, Mateusz ; Szala-Poździej, Agnieszka ; Eppa, Łukasz ; Mitrus, Iwona ; Szmigielska-Kapłon, Anna ; Sobczyk-Kruszelnicka, Małgorzata ; Michalak, Katarzyna ; Gołos, Aleksandra ; Wierzbowska, Agnieszka ; Giebel, Sebastian ; Jamroziak, Krzysztof ; Kowalski, Marek L ; Brzezińska, Olga ; Thiel, Steffen ; Matsushita, Misao ; Jensenius, Jens C ; Gajek, Gabriela ; Cedzyński, Maciej. / Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations. In: Frontiers in Immunology. 2020 ; Vol. 10.

Bibtex

@article{ce091e2be0ae45528a2749b526b5fd6a,
title = "Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations",
abstract = "A prospective study of 312 patients [194 with multiple myeloma (MM) and 118 with lymphomas (LYMPH)] receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT) was conducted. Ficolins are innate immune defense factors, able to distinguish between {"}self{"} {"}abnormal self,{"} and {"}non-self{"} and contribute to the elimination of the last two by direct opsonization and/or initiation of complement activation via the lectin pathway. Concentrations of ficolin-1, ficolin-2, and ficolin-3 in serially taken serum samples were determined as were the polymorphisms of the corresponding (FCN1, FCN2, and FCN3) genes. Serum samples were collected before conditioning chemotherapy, before HSCT, and once weekly post-HSCT (four to five samples in total); some patients were also sampled at 1 and/or 3 months post-transplantation. The control group (C) consisted of 267 healthy unrelated individuals. Median ficolin-1 and ficolin-2 (but not ficolin-3) levels in MM patients' sera taken before chemotherapy were lower (and correspondingly frequencies of the lowest concentrations were higher) compared with controls. That appeared to be associated with the malignant disease itself rather than with post-HSCT complications (febrile neutropenia, infections accompanied, or not with bacteremia). Higher frequencies of the FCN1 genotype G/A-C/C-G/G (corresponding to polymorphisms at positions -542, -144, and +6658, respectively) and FCN2 gene heterozygosity for the -857 C>A polymorphism were found among patients diagnosed with MM compared with the C group. Furthermore, FCN2 G/G homozygosity (-557 A>G) was found more frequently and heterozygosity G/T at +6424 less frequently among LYMPH patients than among the healthy subjects. Heterozygosity for +1637delC mutation of the FCN3 gene was more common among patients diagnosed with lymphomas who experienced hospital infections. Although no evidence for an association of low ficolin-1 or ficolin-2 with infections during neutropenia following chemotherapy before HSCT was found, we observed a possible protective effect of ficolins during follow-up.",
author = "{\'S}wierzko, {Anna S} and Mateusz Michalski and Anna Soko{\l}owska and Mateusz Nowicki and Agnieszka Szala-Po{\'z}dziej and {\L}ukasz Eppa and Iwona Mitrus and Anna Szmigielska-Kap{\l}on and Ma{\l}gorzata Sobczyk-Kruszelnicka and Katarzyna Michalak and Aleksandra Go{\l}os and Agnieszka Wierzbowska and Sebastian Giebel and Krzysztof Jamroziak and Kowalski, {Marek L} and Olga Brzezi{\'n}ska and Steffen Thiel and Misao Matsushita and Jensenius, {Jens C} and Gabriela Gajek and Maciej Cedzy{\'n}ski",
note = "Copyright {\textcopyright} 2020 {\'S}wierzko, Michalski, Soko{\l}owska, Nowicki, Szala-Po{\'z}dziej, Eppa, Mitrus, Szmigielska-Kap{\l}on, Sobczyk-Kruszelnicka, Michalak, Go{\l}os, Wierzbowska, Giebel, Jamroziak, Kowalski, Brzezi{\'n}ska, Thiel, Matsushita, Jensenius, Gajek and Cedzy{\'n}ski.",
year = "2020",
month = jan,
doi = "10.3389/fimmu.2019.03097",
language = "English",
volume = "10",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations

AU - Świerzko, Anna S

AU - Michalski, Mateusz

AU - Sokołowska, Anna

AU - Nowicki, Mateusz

AU - Szala-Poździej, Agnieszka

AU - Eppa, Łukasz

AU - Mitrus, Iwona

AU - Szmigielska-Kapłon, Anna

AU - Sobczyk-Kruszelnicka, Małgorzata

AU - Michalak, Katarzyna

AU - Gołos, Aleksandra

AU - Wierzbowska, Agnieszka

AU - Giebel, Sebastian

AU - Jamroziak, Krzysztof

AU - Kowalski, Marek L

AU - Brzezińska, Olga

AU - Thiel, Steffen

AU - Matsushita, Misao

AU - Jensenius, Jens C

AU - Gajek, Gabriela

AU - Cedzyński, Maciej

N1 - Copyright © 2020 Świerzko, Michalski, Sokołowska, Nowicki, Szala-Poździej, Eppa, Mitrus, Szmigielska-Kapłon, Sobczyk-Kruszelnicka, Michalak, Gołos, Wierzbowska, Giebel, Jamroziak, Kowalski, Brzezińska, Thiel, Matsushita, Jensenius, Gajek and Cedzyński.

PY - 2020/1

Y1 - 2020/1

N2 - A prospective study of 312 patients [194 with multiple myeloma (MM) and 118 with lymphomas (LYMPH)] receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT) was conducted. Ficolins are innate immune defense factors, able to distinguish between "self" "abnormal self," and "non-self" and contribute to the elimination of the last two by direct opsonization and/or initiation of complement activation via the lectin pathway. Concentrations of ficolin-1, ficolin-2, and ficolin-3 in serially taken serum samples were determined as were the polymorphisms of the corresponding (FCN1, FCN2, and FCN3) genes. Serum samples were collected before conditioning chemotherapy, before HSCT, and once weekly post-HSCT (four to five samples in total); some patients were also sampled at 1 and/or 3 months post-transplantation. The control group (C) consisted of 267 healthy unrelated individuals. Median ficolin-1 and ficolin-2 (but not ficolin-3) levels in MM patients' sera taken before chemotherapy were lower (and correspondingly frequencies of the lowest concentrations were higher) compared with controls. That appeared to be associated with the malignant disease itself rather than with post-HSCT complications (febrile neutropenia, infections accompanied, or not with bacteremia). Higher frequencies of the FCN1 genotype G/A-C/C-G/G (corresponding to polymorphisms at positions -542, -144, and +6658, respectively) and FCN2 gene heterozygosity for the -857 C>A polymorphism were found among patients diagnosed with MM compared with the C group. Furthermore, FCN2 G/G homozygosity (-557 A>G) was found more frequently and heterozygosity G/T at +6424 less frequently among LYMPH patients than among the healthy subjects. Heterozygosity for +1637delC mutation of the FCN3 gene was more common among patients diagnosed with lymphomas who experienced hospital infections. Although no evidence for an association of low ficolin-1 or ficolin-2 with infections during neutropenia following chemotherapy before HSCT was found, we observed a possible protective effect of ficolins during follow-up.

AB - A prospective study of 312 patients [194 with multiple myeloma (MM) and 118 with lymphomas (LYMPH)] receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT) was conducted. Ficolins are innate immune defense factors, able to distinguish between "self" "abnormal self," and "non-self" and contribute to the elimination of the last two by direct opsonization and/or initiation of complement activation via the lectin pathway. Concentrations of ficolin-1, ficolin-2, and ficolin-3 in serially taken serum samples were determined as were the polymorphisms of the corresponding (FCN1, FCN2, and FCN3) genes. Serum samples were collected before conditioning chemotherapy, before HSCT, and once weekly post-HSCT (four to five samples in total); some patients were also sampled at 1 and/or 3 months post-transplantation. The control group (C) consisted of 267 healthy unrelated individuals. Median ficolin-1 and ficolin-2 (but not ficolin-3) levels in MM patients' sera taken before chemotherapy were lower (and correspondingly frequencies of the lowest concentrations were higher) compared with controls. That appeared to be associated with the malignant disease itself rather than with post-HSCT complications (febrile neutropenia, infections accompanied, or not with bacteremia). Higher frequencies of the FCN1 genotype G/A-C/C-G/G (corresponding to polymorphisms at positions -542, -144, and +6658, respectively) and FCN2 gene heterozygosity for the -857 C>A polymorphism were found among patients diagnosed with MM compared with the C group. Furthermore, FCN2 G/G homozygosity (-557 A>G) was found more frequently and heterozygosity G/T at +6424 less frequently among LYMPH patients than among the healthy subjects. Heterozygosity for +1637delC mutation of the FCN3 gene was more common among patients diagnosed with lymphomas who experienced hospital infections. Although no evidence for an association of low ficolin-1 or ficolin-2 with infections during neutropenia following chemotherapy before HSCT was found, we observed a possible protective effect of ficolins during follow-up.

U2 - 10.3389/fimmu.2019.03097

DO - 10.3389/fimmu.2019.03097

M3 - Journal article

C2 - 32047495

VL - 10

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 3097

ER -